NCT00833079已完成1 期
A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 500
- 主要终点
- ISGA score 0 or 1
研究概览
简要总结
The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc. and Protopic® (tacrolimus), 0.1% topical ointment (Astellas Pharma US, Inc.) and to show superiority over vehicle in the treatment of moderate to severe atopic dermatitis.
The secondary objectives are to compare the adverse event (AE) profiles of the two ointments and to investigate their systemic absorption at steady state.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-lactating female, 18 years of age or older.
- •Patient has documented evidence that they have been unresponsive to alternative more traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.
- •If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives).
- •Have confirmed diagnosis of atopic dermatitis using the diagnostic features as described by Hanifin and Rajka.
- •Have an IGSA score of 3 (moderate) or 4 (severe)
- •Have an affected Body Surface Area (BSA) of at least 20%
- •Have a minimum Eczema Area and Severity Index (EASI) score of at least 15
排除标准
- •Mild atopic dermatitis as defined by IGSA score of 0 (clear), 1 (almost clear), or 2 (mild) OR %BSA affected less than 20% OR EASI Score of less than
- •Clinically infected atopic dermatitis at the baseline visit. Tacrolimus is not indicated for the treatment of clinically infected atopic dermatitis
- •Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis
- •Females who are pregnant, lactating or likely to become pregnant during the study.
- •History of allergy or sensitivity to tacrolimus, pimecrolimus, any macrolides such as clindamycin erythromycin
- •Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) and cancer.
- •Use of any nonsteroidal immunosuppressants
- •Regular use of intranasal or inhaled corticosteroids, greater than the equivalent of 2 mg of prednisone/day, within 14 days of the first dosing day.
- •Use of non-sedating histamines are not allowed for at least 7 days prior to the first dosing day or throughout the study.
研究组 & 干预措施
Protopic - Tacrolimus 0.1%
Active Comparator
Protopic, Tacrolimus 0.1% applied for 14 days
干预措施: Protopic - Tacrolimus 0.1% (Drug)
Tacrolimus 0.1% Taro
Experimental
Tacrolimus 0.1% manufactured by Taro applied for 14 days
干预措施: Tacrolimus 0.1% manufactured by Taro (Drug)
Vehicle
Placebo Comparator
Tacrolimus vehicle applied for 14 days
干预措施: Tacrolimus Vehicle manufactured by Taro (Drug)
结局指标
主要结局
ISGA score 0 or 1
时间窗: 14 days
次要结局
- % change in BSA(14 days)
- % change in EASI(14 days)
- % change in ISGA(14 days)
- Safety and adverse event profile(14 days)
研究者
相似试验
尚未招募
2 期
Double blind, placebo controlled study Tacrolimus versus Emmolient in localized sclerodermamorphoea10010761localized sclerodermaNL-OMON31329niversitair Medisch Centrum Sint Radboud20
已完成
不适用
Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed ConditionHealthy VolunteersNCT01080534Panacea Biotec Ltd36
已完成
不适用
Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed ConditionHealthy VolunteersNCT01080469Panacea Biotec Ltd36
已完成
不适用
Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fasting ConditionHealthy VolunteersNCT01080482Panacea Biotec Ltd36
已完成
不适用
Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting ConditionHealthy VolunteersNCT01080456Panacea Biotec Ltd36